HORIZON PHARMA USA, INC. Patient Assistance Program
Patient assistance programs (PAPs) are programs created by drug companies,
such as HORIZON PHARMA USA, INC., to offer free or low cost drugs to individuals who are unable to
pay for their medication. These Programs may also be called indigent drug programs,
charitable drug programs or medication assistance programs. Most of the best known and
most prescribed drugs can be found in these programs. All of the major drug companies
have patient assistance programs, although every company has different eligibility and
application requirements.
The HORIZON PHARMA USA, INC. patient assistance program offers free medication to people
who otherwise cannot afford their medications. Patients must meet financial and other
program specific criteria to be eligible for assistance.
To find out how to apply for medication assistance from the HORIZON PHARMA USA, INC. patient
assistance program, visit our Patient Center and use our Database to search for the medication needed.
For a complete listing of HORIZON PHARMA USA, INC. medications available through
their patient assistance programs, see below:
Horizon By Your Side - Actimmune
|
|
The medications available through this program are:
|
|
Actimmune
(interferon gamma-1b) |
|
|
Horizon By Your Side - Buphenyl & Ravicti
|
|
The medications available through this program are:
|
|
Buphenyl Powder
(sodium phenylbutyrate) |
|
|
Buphenyl Tablet
(sodium phenylbutyrate) |
|
|
Ravicti Liquid
(glycerol phenylbutyrate) |
|
|
Horizon By Your Side - Krystexxa
|
|
The medications available through this program are:
|
|
Krystexxa IV
(pegloticase) |
|
|
Horizon By Your Side - Procysbi
|
|
The medications available through this program are:
|
|
Procysbi
(cysteamine bitartrate delayed-release capsule) |
|
|
Horizon By Your Side - Tepezza
|
|
The medications available through this program are:
|
|
Tepezza
(teprotumumab-trbw) |
|
|
Horizon By Your Side - Uplizna
|
|
The medications available through this program are:
|
|
Uplizna
(inebilizumab-cdon) |
|
|
|